This study developed a novel methodology to correlate genome-scale microRNA (miRNA) expression profiles in a lung squamous cell carcinoma (LUSC) cohort ( = 57) with Surveillance, Epidemiology, and End Results (SEER)-Medicare LUSC patients ( = 33,897) as a function of composite tumor progression indicators of T, N, and M cancer stage and tumor grade. The selected prognostic and chemopredictive miRNAs were extensively validated with miRNA expression profiles of non-small-cell lung cancer (NSCLC) patient samples collected from US hospitals ( = 156) and public consortia including NCI-60, The Cancer Genome Atlas (TCGA; = 1016), and Cancer Cell Line Encyclopedia (CCLE; = 117). Hsa-miR-142-3p was associated with good prognosis and chemosensitivity in all the studied datasets. Hsa-miRNA-142-3p target genes (, , , , , , , , and ) had a significant impact on proliferation in 100% of the tested NSCLC cell lines in CRISPR-Cas9 ( = 78) and RNA interference (RNAi) screening ( = 92). Hsa-miR-142-3p-mediated pathways and functional networks in NSCLC short-term survivors were elucidated. Overall, the approach integrating SEER-Medicare data with comprehensive external validation can identify miRNAs with consistent expression patterns in tumor progression, with potential implications for prognosis and prediction of chemoresponse in large NSCLC patient populations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306800 | PMC |
| http://dx.doi.org/10.3390/ijms22147658 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined results from RS and the sensitivity to endocrine therapy (SET2,3) index of endocrine-related transcription (SET) adjusted for baseline prognostic index (BPI) improve prognostic assessment, and whether SET2,3 predicted benefit from anthracycline-based chemotherapy.
Methods: A blinded retrospective clinical validation of SET2,3 in two randomized treatment arms from the SWOG S8814 trial comparing adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years, versus tamoxifen alone.
Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data.
Int J Mol Sci
July 2021
Mary Babb Randolph Cancer Center, West Virginia University Cancer Institute, West Virginia University, Morgantown, WV 26506, USA.
This study developed a novel methodology to correlate genome-scale microRNA (miRNA) expression profiles in a lung squamous cell carcinoma (LUSC) cohort ( = 57) with Surveillance, Epidemiology, and End Results (SEER)-Medicare LUSC patients ( = 33,897) as a function of composite tumor progression indicators of T, N, and M cancer stage and tumor grade. The selected prognostic and chemopredictive miRNAs were extensively validated with miRNA expression profiles of non-small-cell lung cancer (NSCLC) patient samples collected from US hospitals ( = 156) and public consortia including NCI-60, The Cancer Genome Atlas (TCGA; = 1016), and Cancer Cell Line Encyclopedia (CCLE; = 117). Hsa-miR-142-3p was associated with good prognosis and chemosensitivity in all the studied datasets.
View Article and Find Full Text PDFArticle Synopsis
- * A multi-institutional study involving 166 patients with estrogen receptor positive, HER2-negative breast cancers examined ME3's effectiveness in predicting pathologic complete response (pCR) to neoadjuvant chemotherapy.
- * Results indicated that higher ME3 scores correlated with increased pCR rates and better outcomes, reinforcing ME3's predictive and potentially prognostic capabilities, especially in patients with residual disease.
Joint Region and Nucleus Segmentation for Characterization of Tumor Infiltrating Lymphocytes in Breast Cancer.
Proc SPIE Int Soc Opt Eng
February 2019
Roche Diagnostics, Information Solutions, Belmont, CA, USA.
Histologic assessment of stromal tumor infiltrating lymphocytes (sTIL) as a surrogate of the host immune response has been shown to be prognostic and potentially chemo-predictive in triple-negative and HER2-positive breast cancers. The current practice of manual assessment is prone to intra- and inter-observer variability. Furthermore, the inter-play of sTILs, tumor cells, other microenvironment mediators, their spatial relationships, quantity, and other image-based features have yet to be determined exhaustively and systemically.
View Article and Find Full Text PDFDrug-eluting microarrays to identify effective chemotherapeutic combinations targeting patient-derived cancer stem cells.
Proc Natl Acad Sci U S A
July 2015
J. Crayton Pruitt Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611;
A new paradigm in oncology establishes a spectrum of tumorigenic potential across the heterogeneous phenotypes within a tumor. The cancer stem cell hypothesis postulates that a minute fraction of cells within a tumor, termed cancer stem cells (CSCs), have a tumor-initiating capacity that propels tumor growth. An application of this discovery is to target this critical cell population using chemotherapy; however, the process of isolating these cells is arduous, and the rarity of CSCs makes it difficult to test potential drug candidates in a robust fashion, particularly for individual patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!